YolTech Therapeutics Secures $45 Million Series B Funding to Advance In Vivo Gene Editing Pipeline
核心洞察
YolTech Therapeutics (搜索) closed a $45 million Series B financing round led by AstraZeneca-CICC (搜索) healthcare investment fund to support clinical program advancement and global strategic execution.
The company operates one of the most extensive in vivo gene-editing clinical pipelines globally, with four programs targeting ATTR, familial hypercholesterolemia (搜索), primary hyperoxaluria type 1 (搜索), and β-thalassemia (搜索)/sickle cell disease (搜索).
YolTech's YOLT-201 became the first in vivo gene-editing therapy in China to enter Phase I/IIa clinical trial in 2024, while YOLT-101 achieved first-in-class IND clearance in both China and the United States.
YolTech Therapeutics (搜索), a clinical-stage biotech company pioneering in vivo genome editing therapies, announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC (搜索) healthcare investment fund. The proceeds will support the advancement of YolTech's clinical programs and global strategic execution.
"This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing science into real-world treatments for patients worldwide," said Dr. Yuxuan Wu, Founder and CEO of YolTech.
Comprehensive Gene Editing Platform
Founded in 2021, YolTech has built a fully integrated platform encompassing proprietary CRISPR nucleases (YolCas), base editors (YolBE), and a cutting-edge lipid nanoparticle delivery system (Yol-LNPs), enabling precise, efficient, and tissue-specific gene editing across a broad range of therapeutic areas. The company's therapies are designed for one-time treatment, representing a next-generation approach to in vivo gene editing.
Clinical Pipeline Milestones
YolTech has achieved significant regulatory milestones with its clinical programs. In 2024, the company's lead program YOLT-201, a CRISPR-based therapy for transthyretin amyloidosis (搜索) (ATTR), became the first in vivo gene-editing therapy in China to enter Phase I/IIa clinical trial.
The company has since advanced four clinical-stage programs addressing multiple genetic disorders: ATTR, familial hypercholesterolemia (搜索) (HeFH), primary hyperoxaluria type 1 (搜索) (PH1), and β-thalassemia (搜索)/sickle cell disease (搜索) (TDT/SCD).
Regulatory Breakthrough in Base Editing
YolTech's base-editing therapy YOLT-101, developed for familial hypercholesterolemia (搜索) (HeFH), achieved a notable regulatory milestone by becoming the first in vivo base-editing program to receive IND clearance in both China and the United States, demonstrating the company's ability to navigate dual regulatory pathways.
Manufacturing Capabilities
The company operates a cGMP-compliant manufacturing facility supporting clinical supply through Phase III and early commercial scale-up, ensuring manufacturing consistency and scalability across programs. This infrastructure positions YolTech to support its expanding clinical pipeline as programs advance through development phases.
With one of the most extensive in vivo gene-editing clinical pipelines globally, YolTech continues to lead in the field of therapeutic gene editing, leveraging its integrated platform to address multiple genetic diseases with potentially transformative one-time treatments.